argenx SE (ARGX)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

€720.20

Buy

€730.00

arrow-up€3.00 (+0.41%)

Prices updated at 16 Dec 2025, 16:35 CET

Prices minimum 15 mins delay

Prices in EUR

argenx SE, along with its subsidiaries is engaged in the bio-technical research on drugs and pharma processes for the treatment of oncological, autoimmune and inflammatory diseases.

FTSE EuroFirst 300

-0.47%

Brussels

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Peter K.M. Verhaeghe

CEO

Mr. Tim Van Hauwermeiren, M. Sc.

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

1,639

Head office

Laarderhoogtweg 25

Amsterdam

Netherlands

1101EB

+31 107038441

info@argenx.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. James M. Daly Independent Director	0.09m
Mr. Steven E. Krognes Independent Director	0.09m
Mr. Tim Van Hauwermeiren, M. Sc. Executive Director and Chief Executive Officer	0.76m
Mr. Peter K.M. Verhaeghe Non-Executive Chairman of the Board	0.12m
Dr. J. Donald deBethizy, PhD Independent Director	0.09m
Dr. Pamela M. Klein, M.D. Independent Director	0.07m
Mr. Anthony A. Rosenberg Independent Director	0.08m
Dr. Brian L. Kotzin, M.D. Independent Director	0.05m
Ms. Camilla Sylvest Independent Director	0.07m
Mr. Arjen Lemmen Vice President, Corporate Development and Strategy	-
Ms. Andria Wilk Global Head, Quality	-
Mr. Karl Gubitz Chief Financial Officer	0.55m
Ms. Malini Moorthy General Counsel	-
Dr. Luc Truyen, M.D.,PhD Chief Medical Officer	-
Dr. Ana Cespedes, PhD Independent Director	0.07m
Dr. Peter Ulrichts Chief Scientific Officer	-
Ms. Karen Massey Chief Operating Officer	0.66m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
AXA Pension 2036-2038	57,159,881
AXA Pension 2033-2035	37,528,315
FMR LLC	5,074,684
Samsung Asset Management Co Ltd	2,012,133
Samsung Europe Index Master Equity	2,011,820

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.